Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
Cybin Inc Ordinary Shares CYBN
News
-
Cybin to Participate at the 27th Annual Milken Institute Global Conference
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
Thinking about buying stock in Aquestive Therapeutics, Spruce Biosciences, Vale, Marathon Digital Holdings, or Cybin?
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Announces Oversubscribed Private Placement of U.S. $150 Million
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
Psychedelic stock jumps as Steve Cohen's Point72 snaps up shares
FDA issues guidance on psychedelic drug clinical trials